INTRODUCTION
Adenoviruses are double-stranded linear DNA viruses with a 36-kb genome. Several features of adenovirus have made them a popular choice as a transgene delivery vehicle for therapeutic applications. They have a broad host range, can easily be propagated and purified (4) and have a reasonable cloning capacity. Up to 7.5 kb of heterologous sequence can substitute for the E3 and E1 regions of adenovirus using complementation in 293 cells (5) . Deletions in E4 together with a complementing E4/E1 cell line permits the inclusion of larger inserts up to 10 kb (6) .
The most common approach in generating adenovirus recombinants involves in vivo homologous, intramolecular recombination between overlapping Ad sequences in plasmids and restriction-cleaved Ad viral DNA (10) . However, problems with this approach include high background due to contaminating parental virus, which necessitates repeated rounds of plaque purification, and the low efficiency of in vivo homologous recombination. Other recombinant adenoviral systems have been developed to overcome some of these technical challenges. Several current methods involve generating recombinant adenoviruses utilizing the rec system in Escherichia coli . (1, 6) . The method described in this report utilizes the homing sequence of the intron-encoded endonuclease I-CeuI as a cloning site for direct transgene insertion into a viral plasmid.
Intron-encoded endonucleases are enzymes that are encoded within a group I intron, which mediates the intron's transposition (9) . The intron-encoded endonucleases have an unusual long homing sequence ranging from 15-39 bp, which makes them rare-cutting and ideal to use as cloning sites. The intron encoding I-CeuI is called CeLSU.5 and is found in the large subunit rRNA gene of Chlamydomonas eugametos (7, 8, 11) . The encoded protein I-CeuI has a 26-bp homing site 5 ′ -TAACTATAACGGTCCTAAGGTAG-CGA-3 ′ in which we report to be a very good cloning site for the generation of recombinant adenoviruses.
MATERIALS AND METHODS

Plasmid Constructions
The shuttle plasmid pSV-ICEU I was constructed within a pBluescript ® SK(+) (Stratagene, La Jolla CA, USA) backbone. The cytomegalovirus (CMV) promoter, multiple cloning sites and the bovine growth hormone (BGH) poly(A) were polymerase chain reaction (PCR)-amplified from pcDNA3 (Invitrogen, Carlsbad, CA, USA) using the primers: 5 ′ SV-, 5 ′ -TGCACGCGT -AACTATAACGGTCCTAAGGTAGC -GATCGATTGACATTGAT T-A T TGACTAGT TA T TAATAGTAATC-AATTACG-3 ′ and 3 ′ SV-, 5 ′ -TGCAC -GCGTCGCTACCT TAGGACCGTTA-TAGTTAGCTAGCTCCC CAGCATG-CCTGCTATTGTCTTCCCAATCCT-CCCCCTT-3 ′ with Vent ® DNA Polymerase (New England Biolabs, Beverly MA, USA) at cycle parameters 1 ×(4 min at 94°C, 2 min at 45°C and 5 min at 72°C) and 25 × (1 min at 94°C, 2 min at 55°C and 5 min at 72°C). A 1.2-kb PCR product was purified from a 1% agarose gel slice by a QIAEX II ™Gel Extraction Kit (Qiagen, Chatsworth, CA, USA). The purified 1.2-kb PCR product was digested with Mlu I and
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BioTechniques 26:502-508 (March 1999) cloned into Bss HII-digested pBluescript SK(+) to generate pSV-ICEU I. The PCR-amplified portion was sequenced on a Model 377 Sequencer (PE Biosystems, Foster City, CA, USA) to verify sequence integrity. The plasmid pSV2-ICEU I ( Figure 1B) is derived from pSV-ICEU I and contains a mutation (TACGTA to TAC CAA) that eliminates the Sna BI site in the CMV promoter. This was accomplished by replacing a Kpn I-Nde I fragment from pSV-ICEU I with a Kpn INde I fragment from the plasmid called pCMV (Gary White, Genzyme, unpublished), which carries the mutated Sna BI site within the CMV promoter.
The viral vector pAd vantage was constructed in a multi-step manner, as depicted in Figure 1A . First, pAd2-ICEU I was generated from its parent vector pAd (D. Souza, unpublished). pAd is a pBr322-backbone-based vector, which contains Ad2 sequence nucleotides (nt) 1-357 and nt 3328-10685. A polylinker containing unique restriction sites supplants the Ad2 E1 region. An oligonucleotide containing the I-Ceu I recognition site was cloned into the Spe I and Mlu I within pAd polylinker to generate pAd2-ICEU I.
Second, a Sna BI site was created just outside the inverted terminal repeat (ITR) in pAd2-ICEU I by PCR. The Sna BI recognition site was included within the 5 ′ PCR oligonucleotide that was used to amplify the ITR. The ITR PCR product was cloned into the unique Eco RI and Spe I sites of pAd-ICEU I, replacing the former ITR to create pAd2-ICEU I-Sna BI.
Third, the vector pAdE4/E3-2.9 (Cathy Sookdeo, Genzyme, unpublished), which contains Ad2 sequence from nt 23428 to 3 ′ ITR with a deletion in E3 from nt 27971-30937, was modified to create a Sna BI site flanking the 3 ′ ITR by PCR. The ITR was amplified with a 5 ′ oligonucleotide that introduced the Sna BI site. The ITR product was cloned into the unique Sal I and Avr II sites of pAdE4/E3-2.9, replacing the existing ITR to create pAdE4/E3-2.9 Sna BI.
A triple ligation of BamHI-Bst BI cut pAd2-ICEU I-Sna BI vector with a 5.4 -kb BamHI-Srf I fragment from pAdE4/E3-2.9 Sna BI and a 17-kb Bst BI-Srf I fragment from Ad2 was executed to generate pAd vantage . The ligation was transformed into DH5 ™com-petent cells (Life Technologies, Gaithersburg, MD, USA). Putative recombinant clones were screened by standard mini-prep analysis.
[The pAd vantage vector, the shuttle vector and any precursor vectors will be made available to all interested readers after they fill out a standard material and transfer agreement.]
Preparation of pAd vantage for Cloning
Five micrograms of pAd vantage were digested with a total of 30 U (30 µ L) I -CeuI (New England Biolabs) in 500 µ L 1 × I-CeuI buffer at 37°C over 3 h. Ten units of I-Ceu I were added every hour to achieve a total of 30 U. Twenty units (1 µ L) alkaline phosphatase (Boehringer Mannheim GmbH, Mannheim, Germany) were then added, and the reaction was incubated at 37°C for an additional 20 min. The DNA was extracted twice with equal volumes of (25:24:1, vol/vol) phenol:chloroform: isoamyl alcohol (Life Technologies) and then precipitated by adding 1/16 vol of 5 M NaCl and 2 vol of 100% ethanol. The DNA pellet was resuspended in 20 µ L 1 × TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Two microliters (0.25 µ g ) of vector were used for cloning with threefold molar excess of insert in a total volume of 50 µ L of 1 ×T4 ligation buffer and 1 µ L high-concentration T4 ligase (New England Biolabs). The reaction was incubated at room temperature for a minimum of 1 h.
Cell Culture Medium and Reagents
The 293 cell line was purchased from ATCC (Rockville, MD, USA) and was propagated in Dulbecco's modified Eagle medium (DMEM; high glucose) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Life Technologies). One hundred and sixty three microliters of 5 M NaCl were then added, and samples were incubated at -20°C for 10 min. Cellular debris was pelleted at room t emperature by microcentrifugation at 1 4 000 r pm as above for 15 min. The lysate was transferred, leaving cellular debris behind, and was incubated at 37°C for 1 h with proteinase K (Life Technologies) at a final concentration of 200 µ g/mL. Samples were extracted once with an equal volume of (25:24:1, vol/vol) phenol:chloroform: isoamyl alcohol, and the DNA was precipitated with the addition of 2 vol of 100% ethanol. DNA pellets were resuspended in 50 µ L of 1 × TE, and 5 µ L were used for restriction analysis.
Viral Packaging in 293 Cells
Note: For 10-cm plates, cells were seeded at a density of 1 × 10 6 per plate, and the reagent amounts were doubled. 
RESULTS AND DISCUSSION
Design of Cloning Vectors for Recombinant Adenovirus Construction
The adenoviral vector and shuttle vector were constructed in a stepwise manner (Figure 1, A and B 
Generation of Recombinant Adenovirus Ad2 CMV CFTR
To test the efficiency of the system, a cystic fibrosis transmembrane conductance regulator (CFTR) ∆ F508 recombinant adenovirus was generated. Since the CFTRgene is 4.5 kb in size, it was chosen as a practical virus to make, demonstrating the flexibility of the system to accommodate large inserts. A CFTRgene containing the ∆ F508 mutation was cloned into the Xba I-Apa I sites of pSV2-ICEU I as a 4.5-kb Spe I-Apa I fragment from pCMVCFTR 936c ∆ F508 (D. Souza, unpublished). The gene was then subcloned into pAd vantage to generate pAd vantage -CFTR 508 ( Figure 1C ). One out of sixteen putative pAd vantage -CFTR 508 recombinant colonies screened were positive for transgene insertion, resulting in a 6% cloning efficiency. The clone appeared to be stable in E. coli , as no rearrangements were detected by restriction analysis (data not shown). The low efficiency for this cloning was a result of either a poorly dephosphorylated vector or uncut vector background. The method for preparing the viral vector has been improved since this construct was made. To date, based on five independent experiments, we achieve a 53% cloning efficiency. The method for preparing the viral vector stated in Materials and Methods is current.
DNA from 1 L of a pAd vantage -CFTR 508 culture was isolated using the QIAfilter ™Plasmid Mega Kit and QIAGEN ® -tip 2500 (Qiagen). Twenty micrograms of DNA were digested with Sna BI and then transfected into 293 cells. At day seven, one plaque was picked to infect a single well from a 6-well plate. When most of the cells had rounded and detached from the plate (see Materials and Methods), cells were harvested for Hirt analysis.
Since the virus is cloned, it is not necessary to pick isolated plaques. The whole viral population should be homogeneous, and, therefore, the entire plate can be harvested. However, we have found that we obtain confirmation of viral identity and virus expansion quicker if the first visible plaque is picked and used to infect a small population of cells (6-well seeded at 2.5 × 10 5 cells per well) rather than wait for the entire plate to develop CPE.
Structure of Ad2CMVCFTR ∆ F508 ∆ E3-2.9 was confirmed by restriction analysis of Hirt DNA (Figure 2 ). Lanes 2 and 3 represent parental virus Ad2 ∆ E1 ∆ E3-2.9 (pAd vantage ) and Ad2CMVCFTR ∆ F508 ∆ E3-2.9 Hirt DNA digested with BamHI, respectively. As observed, fragments at 11.4, 7.8, 6.2 and 4.7 kb were detected for Ad2 ∆ E1 ∆ E3-2.9, and additional bands characteristic of CFTR at 2.5, 1.5 and 1.1 kb were detected for Ad2CMV-CFTR ∆ F508 ∆ E3-2.9. Lanes 4 and 5 represent parental virus Ad2 ∆ E1 ∆ E3-2.9 and Ad2CMVCFTR ∆ F508 ∆ E3-2.9 Hirt DNA digested with Psh AI, respectively. As observed, fragments at 27 and 3.0 kb were detected for Ad2 ∆ E1 ∆ E3-2.9, while fragments at 27 and 8.7 kb were detected for Ad2 -CMVCFTR ∆ F508 ∆ E3-2.9. Based on the BamHI and Psh AI diagnostic digestions, the CFTR recombinant virus generated appears to contain the correct genomic structure and is free from parental virus contamination.
Expression of Recombinant Adenovirus Ad2CMVCFTR
We next wanted to demonstrate transgene expression from Ad2CMV-CFTR ∆ F508 ∆ E3-2.9 generated with the pAd vantage system. For this purpose, 293 cells were infected with Ad2 -CMVCFTR ∆ F508 ∆ E3-2.9 or Ad2 CFTR-16 at a multiplicity of infection (MOI) of 10. Sodium butyrate was added to the media at a final concentration of 5 mM to enhance transcription and thus facilitate detection of ∆ F508 CFTR. Cells were harvested 72 h postinfection to determine CFTR production by in vitro phosphorylation assay as previously described (2) . Lanes 3 and 4 in Figure 3 indicate the characteristic band C observed for the mature form of CFTR, while lanes 1 and 2 show only band B form, which is consistent with the ∆ F508 mutation (3).
Second Generation pAd vantage Vectors
The system is limited to expression cassettes that do not contain a Sna BI. At the time the system was designed, we were concerned with the affect that DNA bases that flank the viral ITR's had on viral DNA replication. Upon consulting the literature, we decided that the first generation viral vector should contain a restriction endonuclease recognition site that leaves the minimum number of bases that flank the viral ITR's after enzyme excision of viral DNA from plasmid backbone to minimize possible inhibition of viral DNA replication. Subsequent viral vectors would address the tolerance of additional flanking DNA bases on viral DNA replication.
We are currently testing whether an 18-bp recognition site for the restriction encoded endonuclease I-PpoI would prove fruitful, thus allowing all vectors to be released. With the current pAd vantage vector presented in this manuscript, most expression cassettes can be released. Site-directed mutagenesis can remedy gene cassettes that contain a Sna BI site. We are also working on a second-generation pAd vantage vector that will allow for transgene insertion not only in the E1 region but in the E3 and E4 regions as well. We are screening other commercial intron-encoded endonucleases that will serve as effective enzymes for the manipulation of fulllength adenovirus genome in E. coli .
